Risk Factors for Hospitalization and Transfusion Criteria in Patients With Dengue Virus Infection: A Prospective Observational Study
Status: Recruiting
Location: See location...
Study Type: Observational
SUMMARY
This 3-year prospective observational study aims to identify clinical and laboratory risk factors associated with hospitalization in patients with confirmed dengue virus infection. It also seeks to analyze real-world transfusion practices and their outcomes. The study will be conducted in a second-level hospital in northern Mexico and will follow patients from emergency department entry to clinical resolution or hospital discharge.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 5
Healthy Volunteers: f
View:
• Patients aged ≥5 years
• Laboratory-confirmed dengue infection (NS1, IgM, or PCR)
• First contact at emergency or outpatient services
• Informed consent signed by the patient or legal guardian
Locations
Other Locations
Mexico
Clinica Mexico
RECRUITING
Piedras Negras
Contact Information
Primary
JOSE IVAN RODRIGUEZ DE MOLINA SERRANO, MD, MSc, Ph, Specialist
jefe.urgencias@clinicamexico.com
525525848735
Time Frame
Start Date: 2025-08-01
Estimated Completion Date: 2028-08-30
Participants
Target number of participants: 100
Treatments
Inpatient Confirmed Dengue Cohort
This cohort includes patients aged 5 years and older with laboratory-confirmed dengue virus infection (via NS1 antigen, IgM serology, or PCR) who present to the emergency department or outpatient clinic at Clínica México. Patients are prospectively followed from initial presentation through resolution of illness or hospital discharge. No interventions are administered as part of the study; standard clinical care is provided. Data collection focuses on identifying clinical and laboratory predictors of hospitalization and transfusion, including platelet count, hematocrit changes, bleeding signs, and warning symptoms. Transfusion decisions are made independently by the attending physicians, and their rationale is recorded for analysis.
Related Therapeutic Areas
Sponsors
Leads: Jose Ivan Rodriguez de Molina Serrano